Last reviewed · How we verify
ORM-14540
At a glance
| Generic name | ORM-14540 |
|---|---|
| Sponsor | Orion Corporation, Orion Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Early Phase I Microdosing Study of ORM-14540 and ORM-12741 (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ORM-14540 CI brief — competitive landscape report
- ORM-14540 updates RSS · CI watch RSS
- Orion Corporation, Orion Pharma portfolio CI